Osman Celik

Osman Celik

Auto-generated profile, based on publicly available information

Osman Celik

General Directorate of Turkish Public Hospitals, Republic of Turkey Ministry of Health, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
MEMert Esme
Mert Esme
MKMeltem Koca
Meltem Koca
ADAyse Dikmeer
Ayse Dikmeer
CBCafer Balci
Cafer Balci
NANaim Ata
Naim Ata
SBSUAYIP BIRINCI
SUAYIP BIRINCI
Background: A novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) occurred in China in December 2019 and has spread globally. In this study, we aimed to describe the clinical characteristics and outcomes of hospitalized older adults with coronavirus disease 2019 (COVID-19) in Turkey. Methods: We retrospectively analyzed the clinical data of hospitalized patients aged ≥ 60 years with confirmed COVID-19 from March 11, 2020 to May 27, 2020 using nationwide health database. Results: In this nationwide cohort, a total of 16,942 hospitalized older adults with COVID-19 were enrolled, of whom 8,635 (51%) were women. Mean age was 71.2 ± 8.5 years, ranging from 60 to 113 years. Mortality rate before and after curfew was statistically different (32.2% vs. 17.9%; p < .001, respectively). Through multivariate analysis of the causes of death in older patients, we found that male gender, diabetes mellitus, heart failure, dementia, were all significantly associated with mortality in entire cohort. In addition to abovementioned risk factors, in patients aged between 60 and 79 years, hypertension, chronic kidney disease and cancer and in patients 80 years of age and older malnutrition were also associated with increased risk of mortality. Conclusions: In addition to the results of previous studies with smaller sample size, our results confirmed the age-related relationship between specific comorbidities and COVID-19–related mortality.

28 October 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
FAFevzi Altuntas
Fevzi Altuntas
NANaim Ata
Naim Ata
TYTugce Nur Yigenoglu
Tugce Nur Yigenoglu
SBSemih Bascı
Semih Bascı
MDMehmet Sinan Dal
Mehmet Sinan Dal
SBSuayip Birinci
Suayip Birinci

19 April 2021 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
MSMustafa - Sahin
Mustafa - Sahin
CHCem Haymana
Cem Haymana
IDIbrahim Demirci
Ibrahim Demirci
ITIlker Tasci
Ilker Tasci
RERıfat Emral
Rıfat Emral
Alper SonmezAlper Sonmez
Alper Sonmez
Background: There are scarce published data in differentiated thyroid cancer patients about new coronavirus disease 2019 (COVID‐19) disease outcomes and mortality. Here, we evaluated COVID‐19 infection outcomes and mortality in thyroid cancer patients with COVID‐19 infection.Design and methods: We included a cohort of patients with thyroid cancer with PCR‐confirmed COVID‐19 disease from 11 March to 30 May 2020 from the Turkish Ministry of Health database in our nationwide, retrospective study. We compared the mortality and morbidity of COVID patients with or without thyroid cancer. Univariate and multivariate analyses were used to assess the independent factors for mortality, length of hospital stay and intensive care unit (ICU) admission and mechanical ventilation. We also analysed the effect of radioiodine treatment on severity and death rate of COVID‐19 disease.Results: We evaluated 388 COVID‐19 patients with thyroid cancer [median age: 54 years, interquartile range (IQR) 18 years, males: 23%] and age and gender‐matched 388 COVID‐19 patients without thyroid cancer. Patients with thyroid cancer had a similar mortality ratio compared with the non‐cancer group. Among patients with thyroid cancer, age, presence of diabetes mellitus, asthma/COPD, heart failure, chronic kidney disease, prior coronary artery disease, RAS blocker usage and low lymphocyte count were associated with mortality. Radioactive iodine (RAI) treatment and cumulative radioactive iodine dosage did not negatively affect the severity and mortality of COVID‐19 disease in our patient group.Conclusions: Our study indicated that history of thyroid cancer did not have an increased risk of mortality or morbidity in COVID‐19 disease. Besides, RAI therapy history and doses of radioactive iodine did not affect mortality or outcome.

7 September 2022 in Gulhane Medical Journal
Verified
Journal Article
Closed access
ZAZülfikar Akelma
Zülfikar Akelma
MKMelikşah Keskin
Melikşah Keskin
ŞEŞenay Savaş Erdeve
Şenay Savaş Erdeve
NBNurbanu Bursa
Nurbanu Bursa
OÇOsman Çelik
Osman Çelik
SBSUAYIP BIRINCI
SUAYIP BIRINCI

5 May 2022 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
GÖGülsüm Özkan
Gülsüm Özkan
ŞUŞükrü Ulusoy
Şükrü Ulusoy
YEYunus Erdem
Yunus Erdem
BABülent Altun
Bülent Altun
RYRahmi Yılmaz
Rahmi Yılmaz
SBSUAYIP BIRINCI
SUAYIP BIRINCI
The effect of hypertension (HT) and antihypertensive therapies such as renin-angiotensin-aldosterone system (RAAS) blockers on the disease course in COVID-19 patients is controversial. The purpose of this study was to evaluate the effect of HT and antihypertensive therapies on the course of COVID-19 disease. The age, sex, comorbid diseases, and antihypertensive therapies of 132,790 patients with positive COVID-19 real-time transcriptase polymerase chain reaction (RT-PCR) tests in the Turkish Health Ministry National COVID-19 database between 11 March and 31 May 2020, were examined and analyzed. Forty-one percent of the 132,790 patients in this study (median age: 40, 47.3% female) were hospitalized for treatment, and 4.5% were followed-up in the intensive care unit (ICU). The most frequent comorbid disease, at 19.5%, was HT (n = 25,863). Mortality was determined in 4.9% of HT patients and 1.9% of non-HT patients (p < .001). HT, age, and male gender emerged as independent predictors of hospitalization and admission to the ICU, while HT was not a predictor of mortality. In addition, no adverse effect of any antihypertensive treatment, including RAAS inhibitors, on mortality was detected. Based on Turkish national data, HT is common in COVID-19 patients, but does not appear to be an independent predictor of mortality, and no adverse effect of RAAS inhibitors on COVID-19-related mortality was observed.

27 August 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
MCMurat CAGLAYAN
Murat CAGLAYAN
AGAtaman Gönel
Ataman Gönel
OCOsman Celik
Osman Celik
ASAbdulvahit Sozuer
Abdulvahit Sozuer
MUMustafa Mahir Ulgu
Mustafa Mahir Ulgu
SBSUAYIP BIRINCI
SUAYIP BIRINCI
Background: The blood level of tacrolimus (TAC) used for post-transplant immunosuppression should be within the therapeutic index. Geriatric individuals may be at risk of organ rejection because, in this age group, routine drug use is usually disrupted, and the bioavailability of aging-related drugs is decreased. Objective: The aim of this study was to analyze the age-related variability of blood TAC levels in patients in Turkey. Methods: In this study, 697,616 patients who underwent TAC measurement in the laboratories of public, private, and university hospitals between 2018 and 2020 were identified from the Health-net database of the Ministry of Health. The results of patients aged ≥65 years were compared with those of patients aged <65 years. The differences between the sexes in the same age group were also examined. Data from the Turkish Ministry of Health National Electronic Database were used to design a multicenter retrospective cohort study. Results: The study included 697,616 patients. The mean TAC concentration was 7.2 ± 6.25 ng/mL for all the patients, 7.13 ± 6.7 ng/mL for the female patients, and 7.24 ± 5.96 ng/mL for the male patients. A statistically significant difference in TAC concentration was found between men and women in the general population. Groups aged ≥65 years were compared among themselves. A statistically significant decrease in TAC concentration was found only in the age group of 75–79 years (5.63 ± 4.09 ng/mL) of women compared with the men. In all other age groups, the TAC levels of the men were lower. Conclusions: The proportion of patients with TAC concentrations lower than the therapeutic index was higher in the groups aged ≥65 years. Thus, patients aged ≥65 years may be at risk of organ rejection, as optimum immunosuppression cannot be achieved. In these patients, more frequent drug monitoring and providing training to ensure the compliance of the patient and the patient's relatives in the use of TAC may be recommended.